Know Cancer

forgot password

A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)

Phase 2
18 Years
Open (Enrolling)
Metastatic Colorectal Cancer

Thank you

Trial Information

A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)

EZN-2208 will be administered by i.v. infusion weekly for 3 weeks in 4-week cycles. The
cetuximab infusion will be administered before the EZN-2208 (Arm B) or irinotecan (Arm C)
infusion. Study treatment will be continued until evidence of disease progression,
unacceptable toxicity, or withdrawal of the patient's consent for participation in the

Approximately 220 patients will be enrolled in this study: approximately 100 patients in the
K-RAS mutated arm and approximately 120 patients in the wild-type K-RAS arm.

Inclusion Criteria:

- Patients must meet all of the following criteria to be eligible for enrollment in the

1. Histologically confirmed CRC adenocarcinoma that is metastatic or locally
recurrent CRC that is nonresectable

2. Patients must agree to genetic testing of the original or metastatic CRC tumor
biopsy tissue for K-RAS mutational status.

3. Disease progression

4. Previous therapy with irinotecan, oxaliplatin, and fluoropyrimidine either alone
or in any combination(s). Patients must have radiographically documented
progressive disease while receiving, or within 3 months of receiving, these
agents alone or in combination.

5. No more than 2 prior cytotoxic chemotherapy regimens.

6. Age 18 years or older

7. Measurable disease by RECIST Version 1.1

8. ECOG performance status of 0 or 1

9. Adequate bone marrow, renal, and hepatic function

Exclusion Criteria:

- Patients meeting any of the following exclusion criteria will not be eligible for

1. Known chronic infectious disease

2. Major surgery within 3 weeks before study start

3. Known or suspected brain metastases requiring intervention with steroids and/or
radiation therapy.

4. Prior chemotherapy, immunotherapy, non-investigational agent, or other therapy
used to treat the cancer within 3 weeks before the scheduled administration of

5. History of other primary cancer within 5 years of enrollment, unless

1. Curatively resected non-melanomatous skin cancer, or

2. Curatively resected cervical cancer

6. Lack of recovery to Grade 1 from any reversible side effects related to the
administration of an investigational agent, or other prior treatments for the

7. Any condition such as uncontrollable diabetes, uncontrollable hypertension, or
active infection.

8. Current participation in another clinical study with an investigational agent
and/or use of an investigational drug (not including investigational use of an
approved drug) in the 30 days before the first administration of EZN-2208

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Response Rate

Outcome Time Frame:


Safety Issue:


Principal Investigator

Richard M. Goldberg, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of North Carolina, Chapel Hill


United States: Food and Drug Administration

Study ID:




Start Date:

June 2009

Completion Date:

January 2012

Related Keywords:

  • Metastatic Colorectal Cancer
  • EZN-2208 (PEG-SN38)
  • Carcinoma
  • Colorectal Neoplasms



Location #033 Tucson, Arizona  85724-5024
Location# 042 Alhambra, California  91801
Location # 043 Bakersfield, California  93309
Location# 044 Fullerton, California  92835
Location# 019 La Jolla, California  92093-0698
Location# 046 Long Beach, California  90813
Location# 053 Los Angeles, California  90095
Location# 051 Northridge, California  91235
Location# 045 Pomona, California  91767
Location # 049 Santa Barbara, California  93105
Location # 048 Santa Barbara,, California  93105
Location# 052 Santa Maria, California  93454
Location #027 Stanford, California  94305
Location# 003 Newark, Delaware  19718
Location# 047 Orlando, Florida  32804
Location# 022 Port St. Lucie, Florida  34952
Location# 005 Marietta, Georgia  30060
Location# 009 Chicago, Illinois  60611-2927
Location #050 Terre Haute, Indiana  47802
Location# 029 Worcester, Massachusetts  01655
Location #031 Lebanon, New Hampshire  03756
Location# 007 Bronx, New York  10461
Location # 030 Buffalo, New York  14263
Location# 002 New York, New York  10016
Location# 035 New York, New York  10003
Location# 001 Chapel Hill, North Carolina  27514
Location# 020 Goldsboro, North Carolina  27534
Location# 024 Winston-Salem, North Carolina  27103
Location# 008 Columbus, Ohio  43210
Location# 037 Lancaster, Pennsylvania  17605
Location# 018 Greenville, South Carolina  29615
Location# 004 Memphis, Tennessee  38138
Location #038 Houston, Texas  77584
Location# 011 Lubbock, Texas  79410
Location# 021 San Antonio, Texas  78229